Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.61 |
| ▸ | USP8 | P40818 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14409476 | 0.85 | EPHX2 (0.64) | EPHX2USP8PTGS2CA12CA1 | |
| SCHEMBL4252798 | 0.84 | EPHX2 (0.61) | EPHX2USP8PTGS2CA12CA1 | |
| SCHEMBL4245870 | 0.81 | EPHX2 (0.65) | EPHX2USP8PTGS2CA12CA1 | |
| SCHEMBL4248317 | 0.81 | EPHX2 (0.72) | EPHX2USP8PTGS2ALOX5TBXAS1 | |
| SCHEMBL4252890 | 0.81 | EPHX2 (0.64) | EPHX2USP8PTGS2CA12CA1 | |
| SCHEMBL4247381 | 0.79 | EPHX2 (0.62) | EPHX2USP8PTGS2CA12CA1 | |
| SCHEMBL21935301 | 0.77 | EPHX2 (0.66) | EPHX2ALOX5TBXAS1SLC6A3SIGMAR1 | |
| SCHEMBL8495561 | 0.77 | EPHX2 (0.61) | EPHX2USP8CA12CA1CA2 | |
| SCHEMBL4245877 | 0.76 | EPHX2 (0.59) | EPHX2USP8PTGS2CA12CA1 | |
| SCHEMBL4252882 | 0.76 | EPHX2 (0.67) | EPHX2USP8ALOX5TBXAS1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168948-A1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-03-31 | — | — | EP | claimed |
| EP-1798230-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2007-06-20 | — | — | EP | claimed |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | CHEN GUOQING | 2006-02-23 | — | — | US | claimed |
| US-6995162-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2006-02-07 | — | — | US | claimed |
| CN-1671700-A | Substituted alkylamine derivatives and methods of use | AMGEN INC (US) | 2005-09-21 | — | — | CN | claimed |
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | claimed |
| US-6624174-B2 | Especially for treating a neoplastic disease, retinopathy or age-related macular degeneration | NOVARTIS AG (CH) | 2003-09-23 | — | — | US | claimed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | claimed |
| US-20030032656-A1 | 2-Amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2003-02-13 | — | — | US | claimed |
| EP-1259487-A1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2002-11-27 | — | — | EP | claimed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | claimed |
| WO-2001055114-A1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2001-08-02 | — | — | WO | claimed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058445-B2 | Substituted pyridinecarboxamides for the treatment of cancer | AMGEN INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | EPHX2 592/4885USP8 3723/4885PTGS2 617/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | EPHX2 457/4885USP8 3133/4885PTGS2 300/4885 |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | EPHX2 636/4885USP8 2941/4885PTGS2 347/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | EPHX2 636/4885USP8 2941/4885PTGS2 347/4885 |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | EPHX2 457/4885USP8 3133/4885PTGS2 300/4885 |
| US-20030032656-A1 | 2-Amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | KDR, ERBB2, FLT1 | EPHX2 3000/4885USP8 3973/4885PTGS2 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.